---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-004990"
form_type: "8-K"
ticker: "HRGN"
cik: "0001563665"
company_name: "Harvard Apparatus Regenerative Technology, Inc."
filed_at: "2022-04-01T23:59:59+00:00"
generated_at: "2026-06-26T10:40:57.822888+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Biostage FY2021 net loss widens to $8.0M on $3.3M litigation charge and higher legal costs

## Summary
- Q4 2021 net loss of $5.9M ($0.55/share) vs $1.0M loss in Q4 2020; FY2021 loss $8.0M ($0.79/share).
- Loss increase driven by $3.3M contingency charge for wrongful death litigation and $1.3M legal fees for insurance coverage.
- Operating cash at Dec 31, 2021: $1.2M; management expects funding into early Q3 2022.
- Proceeds of $2.8M from private placements (1,372,464 shares + warrants) helped offset $2.6M operating cash burn.
- R&D costs decreased $0.5M in FY2021; notes payable forgiveness contributed $0.4M gain.

## SEC filing metadata
- accession: 0001558370-22-004990
- form_type: 8-K
- ticker: HRGN
- cik: 0001563665
- company_name: Harvard Apparatus Regenerative Technology, Inc.
- filed_at: 2022-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563665/000155837022004990/0001558370-22-004990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563665/000155837022004990/tmb-20220401x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-004990
- JSON: https://secwatch.observer/filing/0001558370-22-004990.json
- Plain text: https://secwatch.observer/filing/0001558370-22-004990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.